Siwa Therapeutics Website, Blog & Press Pages

Siwa Therapeutics Website, Blog & Press Pages - aVenture

Siwa Therapeutics - Library

2 pages

Science/science
SIWA Therapeutics developed SIWA318H, a humanized monoclonal antibody that targets a biomarker on cells with abnormally high glycolysis and oxidative stress, including cancer and senescent cells.
Senescent Cell Clearing Antibody/senescent-cell-clearing-antibody
SIWA Therapeutics reported that an in vivo preclinical study found its SIWA 318 monoclonal antibody significantly inhibited tumor metastasis, with no observable adverse effects or increase in tumor growth compared with the control group.

2 pages

Listen to our founder and CEO, Lewis Gruber discuss SIWA and 318H!/listen-to-our-founder-and-ceo-lewis-gruber-discuss-siwa-and-318h
Second Annual Healthspan Extension Policy and Regulation Workshop/second-annual-healthspan-extension-policy-and-regulation-workshop
The afternoon featured four presentations. First, Lewis Gruber, CEO of SIWA Corporation, provided an update on removing senescent cells as an anti-aging strategy, including presenting results of an anti-senescent cell monoclonal antibody his company is developing. Link

6 pages

Dr. Thomas Tang Joins Siwa Therapeutics Scientific Advisory Board/dr-thomas-tang-joins-siwa-therapeutics-scientific-advisory-board
SIWA Therapeutics develops monoclonal antibodies to prevent, slow or reverse aging, aging-related and degenerative diseases by reducing senescent cells. Dr. Thomas Tang, CEO of First Dimension BioSciences, joined its Scientific Advisory Board.
In the News: Forbes/in-the-news-forbes
SIWA Therapeutics was mentioned in a Forbes article about senolytic therapies and the future of aging.
In the News: Lewis and Misty Gruber Were Interviewed by Lifespan.io/in-the-news-lewis-and-misty-gruber-were-interviewed-by-lifespan-io
In the News: SIWA Therapeutics Joins the Ranks of SpaceX, Apple & Google with Our Inclusion in MIT Technology Reviews Top 10 Breakthrough Technologies of 2020./in-the-news-siwa-therapeutics-joins-the-ranks-of-spacex-apple-google-with-our-inclusion-in-mit-technology-reviews-top-10-breakthrough-technologies-of-2020
MIT Technology Review selected Anti-Aging Drugs as one of the Top 10 Breakthrough Technologies of 2020 and included SIWA Therapeutics as a “key player” in the category.

1 page

Leadership/leadership
Lewis S. Gruber is CEO, chief scientific officer and co-founder of SIWA Therapeutics and the named inventor on its portfolio of more than 60 global patents. He previously served as interim CEO of ZelleRX and CEO and co-founder of Arryx, Inc.

1 page

Partners/partners
SIWA Therapeutics seeks strategic collaborations with industry, patient support foundations and academia to broaden and accelerate its development pipeline.

1 page

2 pages

Homepage/
Homepage/home
Lewis and Misty Gruber discuss how SIWA 318H, the company’s humanized monoclonal antibody, binds to a biomarker of oxidative stress found on senescent cells and cancer cells as well as dysfunctional cells in general.